FAP and neoplasm: The novel SMDC was electively delivered more than 10% injected dose per gram of MMAE to FAP-positive tumors, with a tumor-to-kidney ratio of 16:1 at 24 h post-injection, which was identified as the best performing SMDC, which has now been prioritized for further clinical development.